Modulation of intrinsic inhibitory checkpoints using nanocarriers to unleash NK cell activity

ABSTRACT: Natural killer (NK) cells provide a powerful weapon mediating immune defense against viral infections, tumor growth, and metastatic spread. NK cells demonstrate great potential for cancer immunotherapy; they can rapidly and directly kill cancer cells in the absence of MHC-dependent antigen presentation and can initiate a robust immune response in the tumor microenvironment (TME). Nevertheless, current NK cell-based immunotherapies have several drawbacks, such as the requirement for ex-vivo expansion of modified NK cells, and low transduction efficiency. Furthermore, to date, no clinical trial has demonstrated a significant benefit for NK-based therapies in patients with advanced solid tumors, mainly due to the suppressive TME. To overcome current obstacles in NK cell-based immunotherapies,

SUBMITTER: Dr. Guy Biber 

PROVIDER: S-SCDT-EMM-2021-14073-T | biostudies-other |

REPOSITORIES: biostudies-other